The FDA's regulatory policies may experience significant changes following the departure of Vinay Prasad, a key figure in the agency's recent decision-making processes.
Drugmakers are closely monitoring how these potential shifts could affect the approval pathways for rare-disease medications, which have been a focal point of Prasad's tenure.
As the agency navigates this transition, the implications for drug development timelines and market access for rare-disease therapies could be substantial.